The CEO of Oculis tells Scrip the Swiss biotech can become a major ophthalmic player and that its lead asset could become the first topical drug treatment for retinal edema.
Armed with proceeds from an oversubscribed Series C financing round, Swiss biotech Oculis S.A. will now advance its novel eye drop formulation OCS-01 into two different Phase III studies, one assessing it as treatment for diabetic macular edema (DME) and another for inflammation and pain following ocular surgery.
Proceeds from the $57m Series C financing, announced 4 May, will also be used for two Phase IIb studies evaluating...
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
Wales-based group launches with $140m series A.
